Prelude Therapeutics/$PRLD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prelude Therapeutics
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Ticker
$PRLD
Sector
Primary listing
Employees
79
Headquarters
Website
PRLD Metrics
BasicAdvanced
$437m
-
-$1.00
-
-
Price and volume
Market cap
$437m
52-week high
$5.54
52-week low
$0.75
Average daily volume
520k
Financial strength
Current ratio
2.028
Quick ratio
1.955
Long term debt to equity
24.858
Total debt to equity
29.445
Profitability
EBITDA (TTM)
-81.17
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-465.30%
Operating margin (TTM)
-495.44%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-39.69%
Return on equity (TTM)
-95.25%
Valuation
Price to revenue (TTM)
20.4
Price to book
4.54
Price to tangible book (TTM)
4.54
Price to free cash flow (TTM)
-7.791
Free cash flow yield (TTM)
-12.83%
Free cash flow per share (TTM)
-0.557
Growth
Revenue change (TTM)
138.86%
Earnings per share change (TTM)
-40.86%
3-year earnings per share growth (CAGR)
-25.31%
What the Analysts think about PRLD
Analyst ratings (Buy, Hold, Sell) for Prelude Therapeutics stock.
PRLD Financial Performance
Revenues and expenses
PRLD Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prelude Therapeutics stock?
Prelude Therapeutics (PRLD) has a market cap of $437M as of May 19, 2026.
What is the P/E ratio for Prelude Therapeutics stock?
The price to earnings (P/E) ratio for Prelude Therapeutics (PRLD) stock is 0 as of May 19, 2026.
Does Prelude Therapeutics stock pay dividends?
No, Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders as of May 19, 2026.
When is the next Prelude Therapeutics dividend payment date?
Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders.
What is the beta indicator for Prelude Therapeutics?
Prelude Therapeutics (PRLD) does not currently have a Beta indicator.